Rafferty Asset Management LLC Has $784,000 Position in Taysha Gene Therapies, Inc. $TSHA

Rafferty Asset Management LLC grew its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 102.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 239,785 shares of the company’s stock after buying an additional 121,102 shares during the period. Rafferty Asset Management LLC’s holdings in Taysha Gene Therapies were worth $784,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of TSHA. Vanguard Group Inc. increased its holdings in shares of Taysha Gene Therapies by 17.9% during the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after purchasing an additional 1,955,486 shares during the period. Octagon Capital Advisors LP boosted its stake in shares of Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after buying an additional 1,892,500 shares during the period. Jefferies Financial Group Inc. boosted its stake in shares of Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies during the second quarter worth approximately $11,178,000. Finally, Geode Capital Management LLC grew its position in Taysha Gene Therapies by 3.5% during the second quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company’s stock worth $8,765,000 after buying an additional 128,840 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Insider Buying and Selling

In other Taysha Gene Therapies news, CEO Sean P. Nolan sold 136,789 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the transaction, the chief executive officer owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kamran Alam sold 78,968 shares of the company’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $375,098.00. Following the sale, the chief financial officer owned 1,467,635 shares in the company, valued at approximately $6,971,266.25. The trade was a 5.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 598,623 shares of company stock valued at $2,822,188 over the last ninety days. 3.78% of the stock is owned by company insiders.

Taysha Gene Therapies Trading Up 1.8%

NASDAQ TSHA opened at $4.57 on Friday. The firm has a market capitalization of $1.25 billion, a PE ratio of -13.85 and a beta of 1.02. The business’s 50-day moving average price is $4.79 and its two-hundred day moving average price is $4.43. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $6.02.

Analysts Set New Price Targets

Several equities analysts have commented on TSHA shares. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. UBS Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. Finally, Chardan Capital restated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Moderate Buy” and an average target price of $10.91.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.